Cargando…
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
Despite some promising results, the majority of patients do not benefit from T cell therapies, as tumors prevent T cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their nature and mechanism of action, oncolytic viruses have features that can help overcom...
Autores principales: | Cervera-Carrascon, Victor, Quixabeira, Dafne C.A., Havunen, Riikka, Santos, Joao M., Kutvonen, Emma, Clubb, James H.A., Siurala, Mikko, Heiniö, Camilla, Zafar, Sadia, Koivula, Teija, Lumen, Dave, Vaha, Marjo, Garcia-Horsman, Arturo, Airaksinen, Anu J., Sorsa, Suvi, Anttila, Marjukka, Hukkanen, Veijo, Kanerva, Anna, Hemminki, Akseli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163046/ https://www.ncbi.nlm.nih.gov/pubmed/32322662 http://dx.doi.org/10.1016/j.omto.2020.03.003 |
Ejemplares similares
-
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
por: Havunen, Riikka, et al.
Publicado: (2021) -
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021) -
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022) -
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022) -
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)